Valerie Morisset
Founder at ELIEM THERAPEUTICS, INC.
Net worth: 2 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Levin | M | 47 | 6 years | |
| Joanne Palmer | F | - |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Liam Ratcliffe | M | 60 | 5 years | |
| Adam Rosenberg | M | 54 | 4 years | |
| Simon Tate | M | 58 | 5 years | |
| David Witty | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Judith Dunn | M | 62 | 3 years | |
| Ged Giblin | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Steven John Green | M | 47 |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Trevor Anthony Mill | M | 53 |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Helen Louise Gaby | F | 56 |
Eliem Therapeutics (UK) Ltd.
 Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Founded in 2019, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Part of Eliem Therapeutics, Inc., the private company is based in Altrincham, UK. | - |
| Joanne Eryl Palmer-Phillips | M | 51 |
Eliem Therapeutics (UK) Ltd.
Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Founded in 2019, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Part of Eliem Therapeutics, Inc., the private company is based in Altrincham, UK. | - |
| Emily Pimblett | F | 40 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Azelby | M | 56 | 3 years | |
| Leone Patterson | F | 61 | 2 years | |
| James B. Bucher | M | 59 | - | |
| Erin Lavelle | F | 46 | 3 years | |
| Mark Versavel | M | 65 | - | |
| Amy Chappell | F | - | - | |
| Susan Franks | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 14 | 70.00% |
| United Kingdom | 7 | 35.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Valerie Morisset
- Personal Network
